Buckingham Asset Management LLC lifted its position in Amgen, Inc. (NASDAQ:AMGN) by 4.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,172 shares of the medical research company’s stock after buying an additional 449 shares during the quarter. Buckingham Asset Management LLC’s holdings in Amgen were worth $2,122,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Commonwealth Bank of Australia lifted its holdings in shares of Amgen by 19.7% in the fourth quarter. Commonwealth Bank of Australia now owns 66,961 shares of the medical research company’s stock worth $13,027,000 after buying an additional 11,040 shares in the last quarter. Phocas Financial Corp. purchased a new stake in shares of Amgen in the fourth quarter worth about $117,000. Duality Advisers LP purchased a new stake in shares of Amgen in the fourth quarter worth about $3,983,000. Chicago Partners Investment Group LLC increased its position in shares of Amgen by 76.9% in the first quarter. Chicago Partners Investment Group LLC now owns 2,485 shares of the medical research company’s stock worth $441,000 after purchasing an additional 1,080 shares during the last quarter. Finally, Foundry Partners LLC increased its position in shares of Amgen by 0.5% in the first quarter. Foundry Partners LLC now owns 97,255 shares of the medical research company’s stock worth $18,477,000 after purchasing an additional 525 shares during the last quarter. 77.29% of the stock is currently owned by hedge funds and other institutional investors.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $193.18, for a total transaction of $386,360.00. Following the transaction, the director now directly owns 15,092 shares in the company, valued at $2,915,472.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 6,000 shares of company stock worth $1,089,180 over the last quarter. Company insiders own 0.25% of the company’s stock.
Shares of NASDAQ AMGN opened at $176.71 on Friday. Amgen, Inc. has a one year low of $166.30 and a one year high of $210.19. The company has a current ratio of 2.77, a quick ratio of 2.53 and a debt-to-equity ratio of 2.71. The company has a market cap of $107.78 billion, a price-to-earnings ratio of 12.27, a price-to-earnings-growth ratio of 2.13 and a beta of 1.14.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, beating analysts’ consensus estimates of $3.45 by $0.11. Amgen had a net margin of 34.00% and a return on equity of 71.02%. The business had revenue of $5.56 billion for the quarter, compared to analysts’ expectations of $5.55 billion. During the same period last year, the business earned $3.47 earnings per share. The business’s quarterly revenue was up .1% on a year-over-year basis. As a group, sell-side analysts predict that Amgen, Inc. will post 13.91 EPS for the current fiscal year.
AMGN has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $217.00 price objective on the stock in a research report on Friday, April 12th. Oppenheimer set a $210.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research report on Friday, May 24th. Cowen restated a “buy” rating and issued a $234.00 price objective on shares of Amgen in a research report on Tuesday, February 26th. Cantor Fitzgerald restated a “hold” rating and issued a $221.00 price objective on shares of Amgen in a research report on Monday, April 1st. Finally, Mizuho set a $208.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research report on Friday, April 12th. Ten analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Amgen has a consensus rating of “Buy” and an average price target of $208.35.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.